
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is a promising investment opportunity with a positive long-term outlook due to its innovative pipeline targeting large-market and orphan indications, with a strong focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. With ongoing clinical development programs for narsoplimab and OMS1029, as well as potential approval for OMS527 in the near future, the company has multiple paths for growth and potential revenue generation. Furthermore, the company's current partnership with Novo Nordisk, as well as its strong commercialization strategy and balanced risk profile, further support a positive outlook on Omeros' stock as it continues to drive revenue, margin expansion, and cash flow growth.
Bears say
Omeros is a biotechnology company with a negative outlook due to potential limitations in enrollment of the sickest patients in its current clinical trials, as well as high barriers to adoption and growth for its products in the competitive transplant market. Additionally, while the company expects YARTEMLEA to become the standard of care for TA-TMA, there are uncertainties surrounding reimbursement and competition for indications involving lectin pathway activation. As such, the company's financial success and stock valuation may be hindered in the long term.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares